证券代码：603538 证券简称：美诺华 公告编号：2025-093 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 〔2025〕10 号）、《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》以及《上海证券交易所上市公司自律监管指南第 1 号——公告格式》的相关 规定，现将宁波美诺华药业股份有限公司（以下简称"公司"或"本公司"）2025 年半年度的募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许[2020]2377 号）核准，公司向社会公开发 行 可 转 换 公 司 债 券 520 万 张 ， 每 张 面 值 100 元 ， 发 行 总 额 为 人 民 币 为人民币 512,697,629.67 元。该募集资金已于 2021 年 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：605388 公司简称：均瑶健康 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn； https://juneyaodairy.com网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 第三节 重要事项 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 公司应当根据重要性原则，说明报告期内公司经营 ...

二、监事会会议审议情况 证券代码：003001 证券简称：中岩大地 公告编号：2025-066 北京中岩大地科技股份有限公司 第三届监事会第二十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京中岩大地科技股份有限公司（以下简称"公司"）第三届监事会第二十八 次会议于 2025 年 8 月 23 日（星期六）在公司会议室以现场结合通讯方式召开。会 议通知已于 2025 年 8 月 19 日以电话、短信等方式通知到各位监事。会议应出席监 事 3 人，实到监事 3 人（其中田义以通讯方式出席会议）。本次会议由监事会主席 田义先生主持，本次监事会会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2025 年 半年度报告》《2025 年半年度报告摘要》（公告编号：2025-068）。 （三）审议通过《关于<2025 年半年度募集资金存放、管理与使用情况的专项 报告>的议案》 表决结果：同意 3 票，反对 0 票，弃权 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度募集資金存放與實際使用情況的專項報告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券 ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of raised funds by Guangdong Marubi Biotechnology Co., Ltd. for the first half of 2025, highlighting the total amount raised, its usage, and the management practices in place to ensure compliance with regulations. Group 1: Fundraising Overview - The company raised a total of RMB 842,140,000.00 from the issuance of 41 million shares at RMB 20.54 per share, with net proceeds amounting to RMB 790,001,978.42 after deducting issuance costs of RMB 52,138,021.58 [1] - As of June 30, 2025, the total amount used from the raised funds was RMB 535,181,303.64, with a remaining balance of RMB 270,426,824.67 in the dedicated fundraising account [1][2] Group 2: Fund Management Practices - The company has established a dedicated fund management system in compliance with relevant regulations, including the opening of special accounts for fundraising and signing of tripartite supervision agreements with sponsors and banks [1] - The remaining balance in the fundraising account as of June 30, 2025, is distributed across various banks, with RMB 236,579,195.01 held in one account and RMB 25,918,241.87 in another [1] Group 3: Fund Usage and Projects - The company has not used idle funds for temporary working capital or to repay bank loans, nor has it changed the use of raised funds for ongoing or new projects [2][3] - The construction of the "Cosmetics Intelligent Manufacturing Factory" has been completed, but production line construction is still pending, with plans for future capacity and project arrangements based on market conditions [2][3] Group 4: Compliance and Reporting - The company has adhered to the fundraising management regulations and has not encountered any significant violations in the use of raised funds [2] - There are no changes in the implementation location or method of the fundraising projects, and no early investments or replacements have occurred [3]

Core Points - The report details the fundraising activities and usage of funds by Shenzhen Biyimi Microelectronics Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations and protecting investor interests [1][2][4] Fundraising Overview - The company raised a total of RMB 95,201.58 million by issuing 17,262,300 shares at RMB 55.15 per share, with a net amount of RMB 86,077.79 million after deducting issuance costs [1] - As of June 30, 2025, the total actual received fundraising amount was RMB 879,222,196.04, with a remaining balance of RMB 218,892,997.78 in the fundraising account [2][4] Fund Usage and Surplus - Cumulative direct investment in fundraising projects amounted to RMB 395,212,306.06, with RMB 69,953,204.26 invested in the current period [2][4] - The company has permanently supplemented working capital with RMB 167,529,096.32 from excess fundraising, and repurchased shares worth RMB 47,364,750.01 [4][6] Fund Management - The company has established a dedicated account storage system for fundraising, ensuring compliance with laws and regulations, and has signed multiple tripartite and quadripartite supervision agreements with banks and underwriters [1][2] - As of June 30, 2025, there were no outstanding financial products held, and all idle funds were managed effectively to generate returns [4][6] Project Status and Adjustments - There were no changes to the fundraising investment projects as of June 30, 2025, and no external transfers or replacements of fundraising projects occurred [5][6] - The company has adjusted the internal investment structure and extended the expected operational dates for certain projects, including the power management series control chip development project and the motor drive control chip development project, to May 2027 [5][6] Compliance and Disclosure - The company has adhered to all relevant laws and regulations regarding the use and disclosure of fundraising, ensuring timely and accurate reporting of fundraising storage and usage [5][6]

Fundraising Overview - The company raised a total of RMB 1,640.03 million by issuing 35.56 million shares at a price of RMB 46.12 per share, with net proceeds after expenses amounting to RMB 1,487.48 million [1][2] - As of June 30, 2025, the balance in the fundraising special account was RMB 187.55 million [1][3] Fund Utilization - The company utilized RMB 669.85 million for fundraising projects and permanently supplemented working capital with RMB 553.53 million from oversubscribed funds [1][4] - The company has not used idle fundraising funds to temporarily supplement working capital during the reporting period [2][4] Cash Management - The company approved the use of up to RMB 900 million of temporarily idle fundraising funds for cash management, ensuring that it does not affect project progress or operational safety [2][3] - A total of RMB 125 million was invested in high-safety, high-liquidity financial products [3][6] Project Investment Status - The company reported that there were no changes in the use of fundraising projects during the reporting period [4][6] - The high-end electronic materials production project and the semiconductor packaging materials project have specific investment amounts and progress, with the latter's investment amount adjusted from RMB 111.66 million to RMB 62.42 million [5][6] Oversubscription Fund Usage - The company permanently supplemented working capital with RMB 147.53 million from oversubscription funds during the reporting period [4][5] - There were no oversubscription funds used for ongoing or new projects, including asset acquisitions [4][5]

Summary of Key Points Core Viewpoint The report outlines the management, storage, and usage of the funds raised by Guangdong Leshi Medical Electronics Co., Ltd. for the first half of 2025, detailing the total amount raised, the current balance, and the specific projects funded. Fundraising Overview - The company raised a total of RMB 385,356,068.13 by issuing 23,998,780 shares at a price of RMB 16.48 per share to 14 specific investors [1][2] - As of the end of 2024, the balance in the fundraising special account was RMB 190,328,551.27, with RMB 9,537,660.29 used in the current year, leaving a balance of RMB 182,230,103.57 as of June 30, 2025 [2][5] Fund Management - The company has established a fundraising management system to enhance the efficiency of fund usage, complying with relevant regulations [2][3] - Funds are stored in special accounts at various banks, including China Construction Bank and Bank of China, specifically for the purpose of managing the raised funds [3][4] Fund Usage - The actual usage of the raised funds for the first half of 2025 is detailed in an attached table, with no changes in project implementation locations or methods reported [7][8] - The company has approved the use of up to RMB 180 million of idle funds for cash management, investing in safe and liquid financial products [7][8] Project Adjustments - The company has decided to extend the timeline for certain projects, such as the "Smart Blood Glucose Monitoring Product Industrialization Project," to October 31, 2026, due to market conditions and operational needs [8][10] - The remaining RMB 5,627.60 million from the "TWS Earphone Production Line Construction Project" will be used for permanent working capital [10][12] Compliance and Reporting - The company confirms that there are no issues with the disclosure of fundraising usage, and all activities comply with regulatory requirements [8][9] - The report was approved by the board of directors on August 14, 2025 [8]

Fundraising Overview - The company raised a total of RMB 436,222,997.10 as of June 30, 2025, from non-public stock issuance, with net proceeds amounting to RMB 423,958,661.65 after deducting underwriting fees of RMB 8,350,195.56 [1][2] - The company also conducted a simplified procedure for issuing stocks to specific targets, raising RMB 227,390,093.92, with a net amount of RMB 222,237,302.60 after deducting issuance costs of RMB 5,152,791.32 [2][3] Fund Management - The company has implemented a special account storage system for the raised funds, ensuring that the funds are managed and used specifically for their intended purposes [3][4] - As of June 30, 2025, the balance in the special account for the non-public issuance was RMB 415,201.13, while the balance for the simplified issuance was RMB 830,942.04 [5][6] Fund Usage - The company temporarily used RMB 70,000,000 of idle funds to supplement working capital, with a commitment to return the funds within 12 months [2][5] - The company has not engaged in cash management with idle funds or used excess funds for permanent working capital or loan repayments during the reporting period [6][7] Project Changes - The company approved a change in the use of funds from the "Annual Production of 68 million square meters of electronic materials expansion project" to the "Annual Production of 86 million square meters of electronic materials technological transformation project," reallocating RMB 171,397,100 [8][12] Compliance and Reporting - The company has adhered to the regulations set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and use of raised funds, ensuring legal and effective usage [7][14] - There were no significant issues in the usage and disclosure of raised funds during the reporting period [7][14]

Fundraising Overview - The company raised a total of RMB 61,198.32 million from its initial public offering, after deducting issuance costs of RMB 4,321.68 million [1] - As of June 30, 2025, the company has unused and idle raised funds totaling RMB 46,899.93 million, which includes interest and investment income [2][12] - The balance of the unused raised funds consists of RMB 8,360.32 million in excess funds and RMB 16,686.09 million in idle funds [2][12] Fund Management and Usage - The company has established special accounts for the management of raised funds, ensuring strict approval procedures for their usage [2] - The company has invested RMB 4,900.00 million of excess funds into its wholly-owned subsidiary, Guangxi Langke Technology Investment Co., Ltd., for the construction of the Langke International Storage Technology Industrial Park [2][3] - The company has signed tripartite supervision agreements with banks and sponsors to regulate the management and usage of raised funds [2][3] Changes in Fund Usage - The company has decided to terminate several fundraising projects, including the "Patent Application, Maintenance, and Operation Project" and the "Flash Application and Mobile Storage Technology Research Platform Expansion Project" due to changes in market conditions and strategic alignment [16][17] - The company has adjusted the implementation content and progress of certain projects, extending the construction period to December 1, 2015, to better align with operational needs [15][18] Financial Management - The company has continued to use excess and idle funds for cash management, investing in low-risk financial products with high liquidity [10][11] - As of June 30, 2025, the company has RMB 46,800.00 million in financial products that have not yet matured [11] Issues Identified - The company identified several instances where funds were improperly paid from the fundraising account, including payments for patent fees and legal fees, which have since been reimbursed [5][6][13] - The company has acknowledged that the actual investment in fundraising projects is only 21.8% of the expected total, indicating a significant delay in project execution [9][18]